Compass Therapeutics Inc’s recent filing unveils that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0 on May 27 ’25. In the deal valued at $2.11 per share,10,000 shares were bought. As a result of this transaction, Schuetz Thomas J. now holds 6,480,825 shares worth roughly $17.5 million.
Then, GORDON CARL L sold 3,571,428 shares, generating $5,678,571 in total proceeds. Upon selling the shares at $1.59, the Director now owns 0 shares.
Before that, ORBIMED ADVISORS LLC sold 3,571,428 shares. Compass Therapeutics Inc shares valued at $5,678,571 were divested by the Director at a price of $1.59 per share. As a result of the transaction, ORBIMED ADVISORS LLC now holds 0 shares, worth roughly $0.0.
A number of analysts have revised their coverage, including Leerink Partners’s analysts, who increased its forecast for the stock in early April from “a Market perform” to “an Outperform”. Guggenheim began covering CMPX with “Buy” recommendation on February 24, 2025. Piper Sandler started covering the stock on February 19, 2025. It rated CMPX as “an Overweight”.
Price Performance Review of CMPX
On Friday, Compass Therapeutics Inc [NASDAQ:CMPX] saw its stock fall -5.26% to $2.7. Over the last five days, the stock has lost -2.88%. Compass Therapeutics Inc shares have risen nearly 211.78% since the year began. Nevertheless, the stocks have risen 86.21% over the past one year. While a 52-week high of $4.08 was reached on 02/11/25, a 52-week low of $0.87 was recorded on 04/01/25.
Levels Of Support And Resistance For CMPX Stock
The 24-hour chart illustrates a support level at 2.61, which if violated will result in even more drops to 2.52. On the upside, there is a resistance level at 2.82. A further resistance level may holdings at 2.93.
How much short interest is there in Compass Therapeutics Inc?
A steep rise in short interest was recorded in Compass Therapeutics Inc stocks on 2025-06-13, growing by 0.48 million shares to a total of 7.39 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 6.91 million shares. There was a rise of 6.45%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 23, 2024 when D. Boral Capital began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
